An In-Depth Look at Stoke Therapeutics Inc’s (STOK) Stock Performance

The stock of Stoke Therapeutics Inc (STOK) has seen a 88.91% increase in the past week, with a 60.93% gain in the past month, and a 133.45% flourish in the past quarter. The volatility ratio for the week is 23.92%, and the volatility levels for the past 30 days are at 14.66% for STOK. The simple moving average for the past 20 days is 54.60% for STOK’s stock, with a 102.94% simple moving average for the past 200 days.

Is It Worth Investing in Stoke Therapeutics Inc (NASDAQ: STOK) Right Now?

Moreover, the 36-month beta value for STOK is 0.76. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The public float for STOK is 28.79M and currently, short sellers hold a 12.34% of that float. On April 02, 2024, STOK’s average trading volume was 950.62K shares.

STOK) stock’s latest price update

Stoke Therapeutics Inc (NASDAQ: STOK)’s stock price has plunge by -8.97relation to previous closing price of 13.49. Nevertheless, the company has seen a 88.91% surge in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-03-27 that Stoke Therapeutics (STOK) gains on meaningful clinical data from STK-001 studies for the treatment of Dravet syndrome.

STOK Trading at 91.71% from the 50-Day Moving Average

After a stumble in the market that brought STOK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.13% of loss for the given period.

Volatility was left at 14.66%, however, over the last 30 days, the volatility rate increased by 23.92%, as shares surge +77.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +147.06% upper at present.

During the last 5 trading sessions, STOK rose by +87.38%, which changed the moving average for the period of 200-days by -2.79% in comparison to the 20-day moving average, which settled at $8.21. In addition, Stoke Therapeutics Inc saw 133.45% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at STOK starting from Allan Jonathan, who sale 5,126 shares at the price of $13.20 back on Mar 28 ’24. After this action, Allan Jonathan now owns 2,598 shares of Stoke Therapeutics Inc, valued at $67,668 using the latest closing price.

Kaye Edward M. MD, the CEO of Stoke Therapeutics Inc, sale 11,150 shares at $6.10 during a trade that took place back on Mar 19 ’24, which means that Kaye Edward M. MD is holding 69,350 shares at $67,999 based on the most recent closing price.

Stock Fundamentals for STOK

Current profitability levels for the company are sitting at:

  • -12.59 for the present operating margin
  • 0.46 for the gross margin

The net margin for Stoke Therapeutics Inc stands at -11.44. The total capital return value is set at -0.56. Equity return is now at value -60.80, with -43.23 for asset returns.

Based on Stoke Therapeutics Inc (STOK), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -39.31. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -15.1.

Currently, EBITDA for the company is -110.04 million with net debt to EBITDA at 1.63. When we switch over and look at the enterprise to sales, we see a ratio of 43.84. The receivables turnover for the company is 137.2for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.99.


To wrap up, the performance of Stoke Therapeutics Inc (STOK) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts